Adriana Smith, Brain-Dead Georgia Mom On Life Support, Gives Birth Via C-Section
Source: Courtesy of Family / Courtesy Photo
After months of being on life support due to a medical emergency linked to blood clots in her brain, Adriana Smith's baby boy was delivered via C-section prematurely on Friday, June 13, according to local Atlanta affiliate 11Alive.
But the miracle birth is a bittersweet one, as Smith's family also has to prepare her funeral.
Speaking with the outlet following the birth of her grandson, Smith's mother, April Newkirk, provided an update on the baby's health after weighing in at 1 pound, 13 ounces and being placed in the NICU.
'He's expected to be OK,' Newkirk shared. 'He's just fighting. We just want prayers for him. Just keep praying for him. He's here now.'
Visibly emotional, Newkirk expressed her feelings about saying a final goodbye to her daughter after months on forced life support due to Georgia's abortion ban.
'It's kind of hard, you know,' she said of her daughter, who turned 31 years old on June 15. 'It's hard to process. I'm her mother. I shouldn't be burying my daughter. My daughter should be burying me.'
'If I could say one more thing to her, I guess I would tell her that I love her and that she was a great daughter,' Newkirk added.
Per Georgia law, most abortions are banned after cardiac activity is detected, which is around six weeks of pregnancy and before many women even realize they are pregnant.
On February 19, Smith, a nurse, was declared brain dead at eight weeks pregnant. Newkirk said doctors then informed her that due to Georgia's abortion law, House Bill 481 or the LIFE Act, they were required to keep Smith on life support until the baby could be delivered, according to 11Alive.
However, the LIFE Act does not explicitly address situations involving brain death, which experts say has caused confusion.
The Georgia Attorney General's Office issued a statement back in May addressing the controversial law.
'There is nothing in the LIFE Act that requires medical professionals to keep a woman on life support after brain death,' said office spokesperson Kara Murray. 'Removing life support is not an action with the purpose to terminate a pregnancy.'
'I'm not saying we would have chosen to terminate her pregnancy. But I'm saying we should have had a choice,' Newkirk previously told the outlet of her daughter's right to choose. 'I think all women should have a choice about their body. And I think I want people to know that.'
'The same field that she worked in is the same people that failed her,' Newkirk said.
SEE ALSO
Adriana Smith, Brain-Dead Georgia Mom On Life Support, Gives Birth Via C-Section was originally published on hellobeautiful.com
Black America Web Featured Video
CLOSE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
2 days ago
- Boston Globe
The hideous legacy of the conservative Supreme Court decision that overturned Roe v. Wade
After experiencing severe headaches in February, Adriana Smith (no relation to Penny Smith), a registered nurse in Atlanta, went to the hospital twice. Days later, she was found unresponsive in her home. Smith was rushed to the hospital where doctors discovered blood clots in her brain. She was declared brain dead. Advertisement Smith, 30, was two months pregnant with her second child. But because of Georgia's draconian six-week abortion ban, Smith, against her family's wishes, was kept on life support for four months to keep the baby alive. On June 13, her son, weighing 1 pound, 13 ounces, was delivered prematurely via an emergency Cesarean section. Advertisement 'He's expected to be OK,' April Newkirk, Smith's mother, told an Atlanta TV station about her grandson, Chance. 'He's just fighting. We just want prayers for him. Just keep praying for him.' On June 17, Smith was removed from a ventilator, ending another sorrowful chapter in the Republican war against women's bodies. It should also be noted that Smith received more medical attention after she was declared brain dead than she did in the days before her boyfriend woke up to find her gasping for breath. During two visits to the hospital, Smith was given medication but no tests that might have revealed the danger that was discovered only when it was too late to save her. In 2019, Republican Governor Brian Kemp of Georgia signed the Living Infants Fairness and Equality Act, the law that mandated that Smith's body should be kept viable because she was pregnant. It was Everything changed three years ago this month when the conservative-led Supreme Court unsettled nearly 50 years of settled law by overturning Roe v. Wade and allowing states to severely curtail or prohibit abortion. More than 20 states now have abortion restrictions or bans. Of course, the overturning of the 1973 law that legalized abortion did not end the procedure. Women still need health care, and abortion is health care. In fact, abortions have Advertisement Among those unable to seek care elsewhere are some women who have faced dire consequences. According to a These laws aren't pro-life, nor do they protect women or children. On the day that Smith was taken off life support, This Saturday, Smith Advertisement This is an excerpt from , a Globe Opinion newsletter from columnist Renée Graham. . Renée Graham is a Globe columnist. She can be reached at
Yahoo
3 days ago
- Yahoo
Diabetes stocks rally after RFK comments on HHS campaign
Sarah Karlin-Smith of Pink Sheet reported via X: 'RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). His vision is every American wearing 'wearable' in 4 years.' Shares of companies in the continuous glucose monitoring space moved higher intraday, including Tandem Diabetes (TNDM), DexCom (DXCM), Insulet (PODD), Abbott (ABT) and Medtronic (MDT). Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on TNDM: Disclaimer & DisclosureReport an Issue Cisco upgraded, CoreWeave downgraded: Wall Street's top analyst calls Tandem Diabetes initiated with a Hold at Truist Tandem Diabetes announces agreement with Abbott to develop diabetes solutions Tandem Diabetes Care: Strategic Initiatives and Product Launches Drive Long-Term Growth Potential Balanced Outlook on Tandem Diabetes Care: Growth Opportunities Amid Strategic Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 days ago
- Business Wire
Study Finds Trump's Most Favored Nation Drug Proposal Could Still Raise Out-of-Pocket Costs Without PBM Reform
BOSTON--(BUSINESS WIRE)--Out-of-pocket drug costs for seniors may rise under President Trump's Most Favored Nation (MFN) proposal if policymakers do not address the role of pharmacy benefit managers (PBMs), according to a brief released today by the Pioneer Institute. Smith and Popovian's brief hypothesize that under the Inflation Reduction Act (IRA), PBMs faced lost revenue due to federal price controls, leading them to shift costs to patients. According to Pioneer Institute's IRA Tool, out-of-pocket costs rose by 32 p Share The MFN proposal aims to link U.S. drug prices to the lowest prices in developed countries. However, if rebate contracting remains in place, lower drug prices could still translate into higher out-of-pocket costs for seniors, who may be forced to skip medications to avoid the financial burden. 'We can say with confidence that pharmacy benefit managers are profiting substantially from rebates, fees, and concessions tied to popular medications commonly prescribed to seniors,' said Dr. Bill Smith, co-author of the brief with Dr. Robert Popovian. 'These rebate payments can reach into the billions each year, creating strong incentives for PBMs to maintain the current system, even though many seniors on Medicare cannot afford the rising out-of-pocket costs. Policymakers must address this imbalance and ensure drug pricing works for patients, not just middlemen.' Under the current U.S. pharmaceutical market, PBMs negotiate deals with drug manufacturers promising better coverage in exchange for rebates, various concessions, and fees. To fulfill these contracts, PBMs may increase patients' out-of-pocket costs or impose extra paperwork to steer patients toward certain drugs. While generous rebates can sometimes reduce costs and administrative burdens, the system also incentivizes PBMs to favor higher-priced drugs that offer larger rebates, resulting in higher overall patient costs. This rebate system is largely unregulated and operates behind the scenes. PBMs argue rebates help lower overall drug costs and keep insurance premiums down. However, the lack of transparency creates incentives that don't always benefit patients. Smith and Popovian's brief hypothesize that under the Inflation Reduction Act (IRA), PBMs faced lost revenue due to federal price controls, leading them to shift costs to patients. According to Pioneer Institute's IRA Tool, out-of-pocket costs rose by 32 percent on average for nine commonly prescribed drugs, with seven seeing significant increases. 'Simply put, for the drugs with prices lowered by federal controls, seniors ended up paying more out-of-pocket,' said Dr. Popovian. 'If drug prices fall under the President's new policy but the flawed rebate system remains, patients will still struggle to afford their medications, and well-intentioned policies will backfire.' This warning follows last month's launch by Pioneer, a public tool to monitor the real impact of federal drug price controls under the IRA. The Medicare Drug Access Tracker focuses on Medicare patients served by the four largest PBMs, which cover 87 percent of the market, tracking whether price controls improve affordability over time. Pioneer's initial analysis found out-of-pocket costs increased for seven of nine drugs studied. Key findings include an average cost increase from $74.51 to $98.42 and individual drug cost hikes ranging from $10.56 to $316.81. The public can access the tool at and the full study at Dr. William S. Smith is Senior Fellow & Director of Pioneer Life Sciences Initiative. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor's office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer's corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America. Dr. Robert Popovian is the Founder of the strategic consulting firm Conquest Advisors. He also serves as Chief Science Policy Officer at the Global Healthy Living Foundation, Senior Healthy Policy Fellow at the Progressive Policy Institute, and Visiting Health Policy Fellow at the Pioneer Institute. He previously served as Vice President, U.S. Government Relations at Pfizer. One of the country's foremost experts on every significant facet of biopharmaceuticals and the healthcare industry, he is a recognized authority on health economics, policy, government relations, medical affairs, and strategic planning. To learn more about Dr. Popovian please click here. Pioneer empowers Americans with choices and opportunities to live freely and thrive. Working with state policymakers, we use expert research, educational initiatives, legal action and coalition-building to advance human potential in four critical areas: K-12 Education, Health, Economic Opportunity, and American Civic Values.
